Key Takeaways
- • Violet Therapeutics closed a $4.75M seed extension financing led by Lifespan Vision Ventures, with participation from Dementia Discovery Fund, UTEC (University of Tokyo Edge Capital Partners), Ono Venture Investment, and Mass General Brigham Ventures.
- • Capital will fund IND-enabling activities for Violet's lead small molecule program targeting EphB3, a receptor tyrosine kinase implicated in microglia-astrocyte signaling and synaptic loss across multiple neurodegenerative diseases.
- • The EphB3 program represents the first therapeutic candidate to emerge from Violet's proprietary CONNECT platform, which maps cell-cell interaction networks to identify neuroinflammatory and neurodegenerative signaling pathways at scale.
- • Violet's mechanism addresses synaptic loss through glial-mediated synaptic preservation and repair, positioning the company to pursue first-in-class therapeutics capable of halting and potentially reversing cognitive decline in neurodegenerative diseases and aging.
- • Meredith Fisher, founding CEO of Violet and Partner at Mass General Brigham Ventures, emphasized synaptic loss as the strongest predictor of cognitive decline in Alzheimer's disease, noting that few programs currently target this key pathophysiology.
Summary
Violet Therapeutics, a Cambridge-based preclinical-stage biotechnology company, has secured $4.75 million in seed extension funding to advance its therapeutic pipeline for neurodegenerative diseases. The financing round, announced May 13, 2026, was led by Lifespan Vision Ventures with co-investment from four additional institutional backers: Dementia Discovery Fund, UTEC (University of Tokyo Edge Capital Partners), Ono Venture Investment, and Mass General Brigham Ventures.
The capital will be deployed to support IND-enabling activities for Violet's lead small molecule program, which targets EphB3—a receptor tyrosine kinase that mediates microglia-astrocyte signaling implicated in glial dysfunction and synaptic loss. The EphB3 program represents the first therapeutic candidate to emerge from Violet's proprietary CONNECT platform, a technology engine designed to map cell-cell interaction networks at scale and identify signaling pathways driving neuroinflammation and neurodegeneration. The company's therapeutic strategy focuses on glial-mediated synaptic preservation and repair, with the potential to deliver a first-in-class mechanism capable of halting and potentially reversing cognitive decline to restore lost mental functions.
Meredith Fisher, Partner at Mass General Brigham Ventures and founding CEO of Violet, underscored the clinical relevance of the approach: "Synaptic loss is the strongest predictor of cognitive decline for Alzheimer's and other neurodegenerative diseases, yet we have very few programs that address this key pathophysiology." This market insight reflects a significant therapeutic gap in neurodegenerative disease treatment, where most current approaches target downstream pathology rather than addressing synaptic dysfunction at the cellular level. Violet's focus on the EphB3-mediated signaling pathway between microglia and astrocytes—the brain's resident immune and support cells—provides a novel entry point for therapeutic intervention across multiple neurodegenerative indications and age-related cognitive decline.
The capital will be deployed to support IND-enabling activities for Violet's lead small molecule program, which targets EphB3—a receptor tyrosine kinase that mediates microglia-astrocyte signaling implicated in glial dysfunction and synaptic loss. The EphB3 program represents the first therapeutic candidate to emerge from Violet's proprietary CONNECT platform, a technology engine designed to map cell-cell interaction networks at scale and identify signaling pathways driving neuroinflammation and neurodegeneration. The company's therapeutic strategy focuses on glial-mediated synaptic preservation and repair, with the potential to deliver a first-in-class mechanism capable of halting and potentially reversing cognitive decline to restore lost mental functions.
Meredith Fisher, Partner at Mass General Brigham Ventures and founding CEO of Violet, underscored the clinical relevance of the approach: "Synaptic loss is the strongest predictor of cognitive decline for Alzheimer's and other neurodegenerative diseases, yet we have very few programs that address this key pathophysiology." This market insight reflects a significant therapeutic gap in neurodegenerative disease treatment, where most current approaches target downstream pathology rather than addressing synaptic dysfunction at the cellular level. Violet's focus on the EphB3-mediated signaling pathway between microglia and astrocytes—the brain's resident immune and support cells—provides a novel entry point for therapeutic intervention across multiple neurodegenerative indications and age-related cognitive decline.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.